Dimensiones de la aurícula izquierda en pacientes con ictus isquémico criptogénico como método para predecir el desarrollo de fibrilación auricular.

Antonio Cruz Culebras; Paula Pérez Torre; Rocío Vera; Marina Pascual Izco

doi:10.19230/jonnpr.1271

Authors

Antonio Cruz Culebras Unidad de Ictus (Servicio de Neurología) Hospital Universitario Ramón y Cajal.
Paula Pérez Torre Unidad de Ictus (Servicio de Neurología) Hospital Universitario Ramón y Cajal.
Rocío Vera Unidad de Ictus (Servicio de Neurología) Hospital Universitario Ramón y Cajal.
Marina Pascual Izco Servicio de Cardiología. Hospital Universitario Ramón y Cajal.

DOI:

https://doi.org/10.19230/jonnpr.1271

Keywords:

Cryptogenic stroke, atrial fibrillation, left atrial size

Abstract

Objective: To determine whether the left atrial size can predict the development of atrial fibrillation (AF) in patients with embolic stroke of undetermined source (ESUS).

Methods: Patients with ischemic stroke were included prospectively (January 2015-July 2015) when ESUS was suspected. Clinical and cardiac imaging data were recorded. Patients with cardiac failure were excluded.

Results: a total of 55 patients were included. Medium age was 71 years. The proportion of patients who developed AF during the follow-up (1 year) was 23, 63%. 10 % of patients did not have any vascular risk factor. Basal ECG was normal in 98% of cases. The left atrial size volume was 36, 08 ml in patients who developed AF and 27, 14 ml in patients who did not.

Conclusions: In patients with ESUS, left atrial size dimensions do not predict the occurrence of AF.

Downloads

Download data is not yet available.

References

Kolominsky-Rabas PL, Weber M, Gefeller O, Neundoerfer B, Heuschmann PU. Epidemiology of Ischemic Stroke Subtypes According to TOAST Criteria: Incidence, Recurrence, and Long-Term Survival in Ischemic Stroke Subtypes: A Population-Based Study. Stroke. 2001;32(12):2735–40.

Petty GW, Brown RD, Whisnant JP, Sicks JD, Fallon WMO, Wiebers DO. Ischemic Stroke Subtypes : A Population-Based Study of Incidence and Risk Factors. Stroke. 1999;30(12):2513–6.

Marini C, De Santis F, Sacco S, Russo T, Olivieri L, Totaro R, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke. 2005 Jun;36(6):1115–9.

Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg. 2016;50(5):e1–

Hart RG, Diener H-C, Coutts SB, Easton JD, Granger CB, O’Donnell MJ, et al. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol. 2014 Apr;13(4):429–38.

Ntaios G, Papavasileiou V, Lip GYH, Milionis H, Makaritsis K, Vemmou A, et al. Embolic Stroke of Undetermined Source and Detection of Atrial Fibrillation on Follow-Up: How Much Causality Is There? J Stroke Cerebrovasc Dis [Internet]. 2016 Sep 6; Available from: http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2016.08.015

Liao J, Khalid Z, Scallan C, Morillo C, O’Donnell M. Noninvasive cardiac monitoring for detecting paroxysmal atrial fibrillation or flutter after acute ischemic stroke: a systematic review. Stroke. 2007 Nov;38(11):2935–40.

Diener H-C, Easton JD, Granger CB, Cronin L, Duffy C, Cotton D, et al. Design of Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. acetylsalicylic acid in patients with Embolic Stroke of Undetermined Source (RE-SPECTESUS). Int J Stroke. 2015 Dec;10(8):1309–12.

Kernan WN, Ovbiagele B, Kittner SJ, for the Secondary Prevention Guideline Writing Group. Response to Letter Regarding Article, “Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association.”

Stroke. 2015;46(4):e87–9.

Mar J, Álvarez-Sabín J, Oliva J, Becerra V, Casado MÁ, Yébenes M, et al. The costs of stroke in Spain by aetiology: the CONOCES study protocol. Neurologia. 2013 Jul;28(6):332–9.

Masjuan J, Álvarez-Sabín J, Arenillas J, Calleja S, Castillo J, Dávalos A, et al. Plan de asistencia sanitaria al ICTUS II. 2010. Neurología. 2011;26(7):383–96.

Alonso de Leciñana M, Egido JA, Casado I, Ribó M, Dávalos A, Masjuan J, et al. Guidelines for the treatment of acute ischaemic stroke. Neurologia. 2014 Mar;29(2):102–22.

Kolominsky-Rabas PL, Weber M, Gefeller O, Neundoerfer B, Heuschmann PU. Epidemiology of Ischemic Stroke Subtypes According to TOAST Criteria: Incidence, Recurrence, and Long-Term Survival in Ischemic Stroke Subtypes: A Population-Based Study. Stroke. 2001;32(12):2735–40.

Vingerhoets F, Bogousslavsky J, Regli F, Van Melle G. Atrial fibrillation after acute stroke. Stroke. 1993 Jan;24(1):26–30.

Manina G, Agnelli G, Becattini C, Zingarini G, Paciaroni M. 96 hours ECG monitoring for patients with ischemic cryptogenic stroke or transient ischaemic attack. Intern Emerg Med. 2014 Feb;9(1):65–7.

Miller DJ, Khan MA, Schultz LR, Simpson JR, Katramados AM, Russman AN, et al. Outpatient cardiac telemetry detects a high rate of atrial fibrillation in cryptogenic stroke. J Neurol Sci. 2013 Jan 15;324(1-2):57–61.

Camm AJ, Corbucci G, Padeletti L. Usefulness of continuous electrocardiographic monitoring for atrial fibrillation. Am J Cardiol. 2012 Jul 15;110(2):270–6.

Suissa L, Bertora D, Lachaud S, Mahagne MH. Score for the targeting of atrial fibrillation (STAF): a new approach to the detection of atrial fibrillation in the secondary prevention of ischemic stroke. Stroke. 2009 Aug;40(8):2866–8.

Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography. J Am Soc Echocardiogr. 2009;22(2):107–

Chan Y-H, Yiu K-H, Lau K-K, Yiu Y-F, Li S-W, Lam T-H, et al. The CHADS2 and CHA2DS2-VASc scores predict adverse vascular function, ischemic stroke and cardiovascular death in high-risk patients without atrial fibrillation: role of incorporating PR prolongation. Atherosclerosis. 2014 Dec;237(2):504–13.

Tiwari S, Løchen M-L, Jacobsen BK, Hopstock LA, Nyrnes A, Njølstad I, et al. CHA2DS2-VASc score, left atrial size and atrial fibrillation as stroke risk factors in the Tromsø Study. Open Heart. 2016 Sep 6;3(2):e000439.

Bugnicourt J-M, Flament M, Guillaumont M-P, Chillon J-M, Leclercq C, Canaple S, et al. Predictors of newly diagnosed atrial fibrillation in cryptogenic stroke: a cohort study. Eur J Neurol. 2012;20(10):1352–9.

Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012 Jan 12;366(2):120–9.

Ntaios G, Vemmos K, Lip GYH, Koroboki E, Manios E, Vemmou A, et al. Risk Stratification for Recurrence and Mortality in Embolic Stroke of Undetermined Source. Stroke. 2016;47(9):2278–85.

Rodríguez-Yáñez M, Arias-Rivas S, Santamaría-Cadavid M, Sobrino T, Castillo J, Blanco M. High pro-BNP levels predict the occurrence of atrial fibrillation after cryptogenic stroke. Neurology. 2013 Jul 30;81(5):444–7.

Bernstein RA, Di Lazzaro V, Rymer MM, Passman RS, Brachmann J, Morillo CA, et al. Infarct Topography and Detection of Atrial Fibrillation in Cryptogenic Stroke: Results from CRYSTAL AF. Cerebrovasc Dis. 2015;40(1-2):91–6.

Thijs VN, Brachmann J, Morillo CA, Passman RS, Sanna T, Bernstein RA, et al. Predictors for atrial fibrillation detection after cryptogenic stroke: Results from CRYSTAL AF. Neurology. 2016 Jan 19;86(3):261–9.